NCT02530255View on ClinicalTrials.gov

Telomerase Activator and Retinal Amyloid

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

December 31, 2018

Conditions
Alzheimer Disease
Interventions
DIETARY_SUPPLEMENT

cycloastragenol

Oral telomerase activator - cycloastragenol.

DIETARY_SUPPLEMENT

placebo (for cycloastragenol)

placebo comparator, placebo for cycloastragenol.

Trial Locations (1)

54701

Chippewa Valley Eye Clinic, Eau Claire

All Listed Sponsors
collaborator

TA-Sciences

UNKNOWN

lead

Chippewa Valley Eye Clinic

OTHER

NCT02530255 - Telomerase Activator and Retinal Amyloid | Biotech Hunter | Biotech Hunter